French biobank aims to unlock secrets of rare brain vessel diseases
NCT ID NCT07650110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will collect blood samples and medical information from 600 adults with rare diseases affecting blood vessels in the brain and eye, such as CADASIL and cavernous angioma. The goal is to create a long-term biobank that researchers can use to find biomarkers and better understand how these diseases progress. Participants will provide samples and data over time, but this study does not test any new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2038
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For the group of patients with MVCR: * Patients aged between 18 and 80 years at the time of inclusion * Diagnosis confirmed by the detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL, or in another gene responsible for other forms of monogenic cSVD (such as the COL4A1, COL4A2 and HTRA1 genes) or a confirmed diagnosis of MOYA-MOYA (arteriography and/or genetic testing) or cavernoma, cerebral venous thrombosis or a cerebral vascular malformation, including cavernomas * Covered by social security or an equivalent scheme * Written consent. * Patient included in the MVCR cohort For control group * Subject aged between 18 and 80 at the time of inclusion. * Written consent. * Blood pressure \< 140/90 mmHg without treatment or \< 130/80 mmHg if treated and stable for ≥3 months * Covered by social security or a similar scheme * Strictly normal neurological examination (NIHSS=0; no focal deficit) * Normal cognitive examination: MMSE ≥ 26 Exclusion criteria : Common exclusion criteria for patients and control subjects: * A person referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the Public Health Code, defined as: * Pregnant women, women in labour or breastfeeding women * Persons deprived of their liberty by judicial or administrative decision * Persons hospitalised without consent and not subject to a legal protection measure, and persons admitted to a health or social care facility for purposes other than research * Minors * Adults subject to a legal protection measure (guardianship, curatorship or judicial protection), adults unable to give consent and not subject to a legal protection measure * Individuals subject to a withdrawal period for another research study * Patients participating in another interventional research study * Acute or chronic infectious disease Specific exclusion criteria for control subjects * Any identified extra- or intracranial vascular pathology requiring specific management * Known cardiovascular disease (coronary artery disease, arterial disease, atrial fibrillation, heart failure) * Neurological history: stroke, TIA, intracranial haemorrhage, meningitis/encephalitis, head injury with loss of consciousness \>30 mins, * Multiple sclerosis, neurodegenerative disease, active epilepsy, * Current or former smoking (more than 10 pack-years) * Diabetes * Antithrombotic or lipid-lowering treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cadasil are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A balloon that coats heart arteries in drug, no stent left behind
- Can an Anti-Inflammatory drug improve recovery from a rare stroke type?
- Can olive oil and walnuts shield the brain from stroke and memory loss?
- Can brain scans and genes predict CADASIL's course?
- Predicting the unpredictable: new model aims to forecast brain bleeds in moyamoya
- Can a daily pill and a simple physical therapy delay moyamoya strokes?